OBJECTIVE: To evaluate whether counts of circulating colony forming unit-endothelial cells (CFU-ECs), cells co-expressing CD34, CD133, and CD31 (CD34+CD133+CD31+), and CD34+CD45- cells are altered in adolescents with type 1 diabetes and if the changes in counts correlate with endothelial dysfunction. STUDY DESIGN: Adolescents with diabetes (ages 18 to 22 years) and race- and sex-matched control subjects were studied. We assessed circulating CFU-ECs, using colony assays, and CD34+CD133+CD31+ and CD34+CD45- cells, using poly-chromatic flow cytometry. CFU-ECs and CD34+CD133+CD31+ are hematopoietic-derived progenitors that inversely correlate with cardiovascular risk in adults. CD34+CD45- cells are enriched for endothelial cells with robust vasculogenic potential. Vascular reactivity was tested by laser Doppler iontophoresis. RESULTS: Subjects with diabetes had lower CD34+CD133+CD31+ cells, a trend toward reduced CFU-ECs, and increased CD34+CD45- cells compared with control subjects. Endothelium-dependent vasodilation was impaired in subjects with diabetes, which correlated with reductions in circulating CD34+CD133+CD31+ cells. CONCLUSIONS: Long-term sequelae of type 1 diabetes include vasculopathies. Endothelial progenitor cells promote vascular health by facilitating endothelial integrity and function. Lower CD34+CD133+CD31+ cells may be a harbinger of future macrovascular disease risk. Higher circulating CD34+CD45- cells may reflect ongoing endothelial damage. These cells are potential biomarkers to guide therapeutic interventions to enhance endothelial function and to prevent progression to overt vascular disease. Copyright (c) 2010 Mosby, Inc. All rights reserved.
OBJECTIVE: To evaluate whether counts of circulating colony forming unit-endothelial cells (CFU-ECs), cells co-expressing CD34, CD133, and CD31 (CD34+CD133+CD31+), and CD34+CD45- cells are altered in adolescents with type 1 diabetes and if the changes in counts correlate with endothelial dysfunction. STUDY DESIGN: Adolescents with diabetes (ages 18 to 22 years) and race- and sex-matched control subjects were studied. We assessed circulating CFU-ECs, using colony assays, and CD34+CD133+CD31+ and CD34+CD45- cells, using poly-chromatic flow cytometry. CFU-ECs and CD34+CD133+CD31+ are hematopoietic-derived progenitors that inversely correlate with cardiovascular risk in adults. CD34+CD45- cells are enriched for endothelial cells with robust vasculogenic potential. Vascular reactivity was tested by laser Doppler iontophoresis. RESULTS: Subjects with diabetes had lower CD34+CD133+CD31+ cells, a trend toward reduced CFU-ECs, and increased CD34+CD45- cells compared with control subjects. Endothelium-dependent vasodilation was impaired in subjects with diabetes, which correlated with reductions in circulating CD34+CD133+CD31+ cells. CONCLUSIONS: Long-term sequelae of type 1 diabetes include vasculopathies. Endothelial progenitor cells promote vascular health by facilitating endothelial integrity and function. Lower CD34+CD133+CD31+ cells may be a harbinger of future macrovascular disease risk. Higher circulating CD34+CD45- cells may reflect ongoing endothelial damage. These cells are potential biomarkers to guide therapeutic interventions to enhance endothelial function and to prevent progression to overt vascular disease. Copyright (c) 2010 Mosby, Inc. All rights reserved.
Authors: David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman Journal: N Engl J Med Date: 2005-12-22 Impact factor: 91.245
Authors: Mervin C Yoder; Laura E Mead; Daniel Prater; Theresa R Krier; Karim N Mroueh; Fang Li; Rachel Krasich; Constance J Temm; Josef T Prchal; David A Ingram Journal: Blood Date: 2006-10-19 Impact factor: 22.113
Authors: L Sibal; A Aldibbiat; S C Agarwal; G Mitchell; C Oates; S Razvi; J U Weaver; J A Shaw; P D Home Journal: Diabetologia Date: 2009-05-30 Impact factor: 10.122
Authors: Cindy J M Loomans; Eelco J P de Koning; Frank J T Staal; Maarten B Rookmaaker; Caroline Verseyden; Hetty C de Boer; Marianne C Verhaar; Branko Braam; Ton J Rabelink; Anton-Jan van Zonneveld Journal: Diabetes Date: 2004-01 Impact factor: 9.461
Authors: David A Ingram; Izlin Z Lien; Laura E Mead; Myka Estes; Daniel N Prater; Ethel Derr-Yellin; Linda A DiMeglio; Laura S Haneline Journal: Diabetes Date: 2007-12-17 Impact factor: 9.461
Authors: Juan C Acosta; David M Haas; Chandan K Saha; Linda A Dimeglio; David A Ingram; Laura S Haneline Journal: Am J Obstet Gynecol Date: 2010-12-16 Impact factor: 8.661
Authors: Santiago J Assaf; Daniel V Chang; Christina J Tiller; Jeffrey A Kisling; Jamie Case; Julie A Mund; James E Slaven; Zhangsheng Yu; Shawn K Ahlfeld; Brenda Poindexter; Laura S Haneline; David A Ingram; Robert S Tepper Journal: Pediatr Pulmonol Date: 2014-12-02
Authors: Julie A Mund; Harlan Shannon; Anthony L Sinn; Shanbao Cai; Haiyan Wang; Kamnesh R Pradhan; Karen E Pollok; Jamie Case Journal: Angiogenesis Date: 2013-07-23 Impact factor: 9.596
Authors: Carlo Palombo; Michaela Kozakova; Carmela Morizzo; Laura Gnesi; Maria Chiara Barsotti; Paolo Spontoni; Francesco Massart; Paolo Salvi; Alberto Balbarini; Giuseppe Saggese; Rossella Di Stefano; Giovanni Federico Journal: Cardiovasc Diabetol Date: 2011-10-08 Impact factor: 9.951
Authors: Emily K Blue; BreAnn M Sheehan; Zia V Nuss; Frances A Boyle; Caleb M Hocutt; Cassandra R Gohn; Kaela M Varberg; Jeanette N McClintick; Laura S Haneline Journal: Diabetes Date: 2015-02-26 Impact factor: 9.461
Authors: Emily K Blue; Robert DiGiuseppe; Ethel Derr-Yellin; Juan Carlos Acosta; S Louise Pay; Helmut Hanenberg; Megan M Schellinger; Sara K Quinney; Julie A Mund; Jamie Case; Laura S Haneline Journal: Pediatr Res Date: 2013-11-14 Impact factor: 3.756